

RESEARCH ARTICLE

Open Access

# Indoor pollutant exposure is associated with heightened respiratory symptoms in atopic compared to non-atopic individuals with COPD

Deepak A Kaji<sup>1</sup>, Andrew J Belli<sup>1</sup>, Meredith C McCormack<sup>1,2</sup>, Elizabeth C Matsui<sup>3</sup>, D'Ann L Williams<sup>2</sup>, Laura Paulin<sup>1</sup>, Nirupama Putcha<sup>1</sup>, Roger D Peng<sup>4</sup>, Gregory B Diette<sup>1,2</sup>, Patrick N Breyse<sup>2</sup> and Nadia N Hansel<sup>1,2\*</sup>

## Abstract

**Background:** Indoor particulate matter (PM) has been linked to respiratory symptoms in former smokers with COPD. While subjects with COPD and atopy have also been shown to have more frequent respiratory symptoms, whether they exhibit increased susceptibility to PM as compared to their non-atopic counterparts remains unclear. The aim of this study was to determine whether atopic individuals with COPD have greater susceptibility to PM compared to non-atopic individuals with COPD.

**Methods:** Former smokers with moderate to severe COPD were enrolled (n = 77). PM<sub>2.5</sub>, PM with diameter <2.5 micrometers, was measured in the main living area over three one-week monitoring periods at baseline, 3, and 6 months. Quality of life, respiratory symptoms and medication use were assessed by questionnaires. Serum was analyzed for specific IgE for mouse, cockroach, cat, dog and dust mite allergens. Atopy was established if at least one test was positive. Interaction terms between PM and atopy were tested and generalized estimating equation analysis determined the effect of PM concentrations on health outcomes. Multivariate models were adjusted for age, sex, education, race, season, and baseline lung function and stratified by atopic status.

**Results:** Among atopic individuals, each 10 µg/m<sup>3</sup> increase in PM was associated with higher risk of nocturnal symptoms (OR, 1.95; P = 0.02), frequent wheezing (OR, 2.49; P = 0.02), increased rescue medication use (β = 0.14; P = 0.02), dyspnea (β = 0.23; P < 0.001), higher St. George's Respiratory Quality of Life score (β = 2.55; P = 0.01), and higher breathlessness, cough, and sputum score (BCSS) (β = 0.44; P = 0.01). There was no association between PM and health outcomes among the non-atopic individuals. Interaction terms between PM<sub>2.5</sub> and atopy were statistically significant for nocturnal symptoms, frequency of rescue medication use, and BCSS (all P < 0.1).

**Conclusions:** Individuals with COPD and atopy appear to be at higher risk of adverse respiratory health effects of PM exposure compared to non-atopic individuals with COPD.

**Keywords:** COPD, Atopy, Allergic sensitization, Pollutants, Particulate matter, PM, Indoor air, Susceptibility

## Background

Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation [1] and is a serious public health concern as it is the third leading cause of death in the United States [2]. COPD manifests after extended inhalation exposure to toxic agents such

as cigarette smoke [3], and continued exposure among those with established disease is associated with worse disease severity [1]. We have previously shown that indoor air pollution, particularly particulate matter less than 2.5 micron in diameter (PM<sub>2.5</sub>), even at relatively low concentrations observed in US homes, was associated with increased respiratory symptoms and risk of severe COPD exacerbations in former smokers with moderate to severe COPD [4]. In addition, the presence of allergic sensitization has also been linked to worse

\* Correspondence: nhansel1@jhmi.edu

<sup>1</sup>Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA

<sup>2</sup>Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA

Full list of author information is available at the end of the article

respiratory symptoms in the same cohort of adults with COPD [5].

There is some evidence to suggest that allergic sensitization to aeroallergens is associated with increased susceptibility to the adverse health effects of PM in patients with asthma. For example, several studies suggest that atopic individuals have worse outcomes upon exposure to PM and other environmental pollutants compared to non-atopics with asthma [6-8]; however these results have not been consistent. For instance, some studies in asthma have not shown differential health effects of PM by atopic status; [9] other studies suggest that exposure to air pollutants is more deleterious in non-atopic than in atopic asthmatics [10,11]. Whether atopic individuals with COPD are more susceptible to the effect of PM exposure compared to those without atopy has not previously been studied. The goal of this analysis was to investigate whether atopic individuals with moderate to severe COPD were more susceptible to the adverse effects of PM<sub>2.5</sub> on respiratory health than non-atopic individuals.

## Methods

### Participant recruitment

Participants and methods were previously described [4]. Briefly, 84 former smokers with COPD meeting the following inclusion criteria were recruited from the Baltimore area: 1) age  $\geq 40$  years, 2) post bronchodilator FEV<sub>1</sub>  $\leq 80\%$  predicted, 3) FEV<sub>1</sub>/FVC  $< 70\%$ , and 4)  $> 10$  pack years smoking, but having quit  $> 1$  year prior to enrollment. Current non-smoking status was confirmed by requiring an exhaled carbon monoxide level  $\leq 6$  ppm at the time of recruitment [12]. Participants reporting a history of asthma ( $n = 7$ ) were excluded from the current analyses as previously done in Jamieson et al. [5]. Participants provided written informed consent and the Johns Hopkins Medical Institutional Review Board approved the protocol.

### Air quality assessment

Air sampling was performed for one week at baseline, 3 and 6 months in the main living area, identified as a room, other than the bedroom, where the participant reported spending the most time and the bedroom. Indoor air sampling for PM<sub>2.5</sub> and nitrogen dioxide (NO<sub>2</sub>) was conducted as described previously [9]. The limit of detection (LOD) for PM<sub>2.5</sub> was 0.64  $\mu\text{g}/\text{m}^3$ .

### Clinical evaluation

Clinic visits occurred between day 4 and 7 of the air monitoring period at baseline, 3 and 6 months. Validated questionnaires assessed quality of life (St. George's Respiratory Questionnaire (SGRQ)) [13], dyspnea (Medical Research Council (MRC) dyspnea scale) [14], and respiratory health. Presence of cough or phlegm was determined

by a positive response to either of the following questions from the American Thoracic Society Division of Lung disease (ATS-DLD) Questionnaire [15]: "Do you usually have a cough?" or "Do you usually bring up phlegm from your chest" at each visit and was dichotomized to "yes" or "no." Subjects reported whether they experienced wheeze in the last four weeks and responses were dichotomized to "frequent" if they reported symptoms almost every day, several days a week, or a few days a month and "infrequent" if they responded only with respiratory infections, or not at all. Nocturnal symptoms defined as coughing or breathing that disturbs sleep was dichotomized to "yes" or "no". Frequency of rescue medication use (0, 1, 2, 3 or  $> 4$  times daily) and symptoms as assessed by Breathlessness, Cough and Sputum Score (BCSS) [16] were assessed by daily diary. Responses were averaged over each one-week monitoring period. Spirometry, before and after albuterol, was performed according to American Thoracic Society (ATS) criteria [17,18]. Serum was analyzed for specific IgE by ImmunoCAP (Phadia, ThermoFisher, USA) for mouse, cockroach, cat, dog and dust mite allergens. A participant was considered atopic if at least one test was at or above the level of detection (0.1 kUA/L).

Exacerbations over the duration of study were assessed by questionnaires at each clinic visit and by monthly telephone calls. Any exacerbation was defined as worsening respiratory symptoms requiring antibiotics, oral steroids or an acute care visit. Severe exacerbations were defined as worsening respiratory symptoms leading to an Emergency department (ED) visit or hospitalization.

### Statistical analysis

Descriptive statistics were analyzed using likelihood-ratio tests and t-tests, as appropriate. At each time point, the PM<sub>2.5</sub> concentrations were used as exposure variables in generalized estimating equations models [15], in order to account for the correlation arising from repeated measures of the outcomes over time; adjusting for age, sex, education, season (spring/summer vs. fall/winter) and pre-bronchodilator % predicted FEV<sub>1</sub>. In sensitivity analysis, we also included the use of inhaled corticosteroids (ICS) as a confounding variable. Interaction terms were used in the final models to formally test for interactions between PM<sub>2.5</sub> and atopy. Because significant interactions between PM<sub>2.5</sub> and atopy were identified, analyses investigating the association between PM<sub>2.5</sub> and COPD outcomes were stratified by atopic status. To evaluate the effect of PM<sub>2.5</sub> on respiratory health, continuous and binary outcomes were analyzed using linear and logistic regression models, respectively, with PM<sub>2.5</sub> included as a continuous predictor. All models with a generalized estimating equations approach assumed exchangeable correlations. The primary analyses included effects of the main living area as this was found to be the most important area

of exposure in regards to COPD outcomes [4]. Investigation of interactions with atopy and associations between NO<sub>2</sub> and bedroom PM<sub>2.5</sub> with health outcomes were included as secondary analyses.

All analyses were performed with StataSE statistical software, version 11.0 (Stata Corp, College Station, TX). A *P* value less than 0.05 was considered statistically significant for main effects and a *P* value less than 0.10 was considered statistically significant for interactions for modestly sized populations, as previously done and recommended by Selvin et al. [19].

## Results

### Baseline participant characteristics and pollutant concentrations

All participants (n = 77) had moderate or severe COPD with a mean baseline post-bronchodilator FEV<sub>1</sub> % predicted of 52.3%. As previously published, a third (30%) of individuals were atopic (17 tested positive to cockroach, 16 to house dust mite, 7 to dog, 6 to cat and 1 to mouse allergen). At baseline, atopic participants with COPD were significantly more likely to report the presence of wheeze, nocturnal cough, and health care utilization in the previous one year compared to non-atopic subjects [5]. There was no difference in reported baseline quality of life (SGRQ score), dyspnea (MMRC score), or prevalence of common comorbidities (Table 1).

Atopic and non-atopic participants reported spending similar amounts of time indoors (90% and 92%, respectively). At baseline, the median PM<sub>2.5</sub> (IQR) concentrations tended to be higher in homes of atopic individuals (12.3 (4.7, 26.8) µg/m<sup>3</sup> vs. 9.0 (2.6, 29.3) µg/m<sup>3</sup>, *p* = 0.07). There were no significant differences in regards to type of housing, heating, or cooking or presence of air nicotine or report of other smokers in the home between those with and without atopy (data not shown).

### Association of indoor pollutant concentrations and respiratory health

In bivariate analyses, increasing PM<sub>2.5</sub> concentrations in the main living area were associated with increased frequency of wheeze, rescue medication use, nocturnal symptoms and worse quality of life (SGRQ) among atopic individuals (Table 2). Among the non-atopic individuals, there were no statistically significant associations between PM and respiratory outcomes.

Similarly, after adjustment for confounders in multivariate analyses, indoor PM<sub>2.5</sub> in the main living area was significantly associated with respiratory health outcomes among atopic individuals but not among non-atopic individuals (Table 3) (Figure 1). Specifically, among atopic individuals, increasing PM<sub>2.5</sub> concentrations were significantly associated with increased risk of nocturnal symptoms (OR 1.95, *p* = 0.02), BCSS scores ( $\beta$  = 0.44, *p* = 0.01)

**Table 1 Baseline participant characteristics**

Participant characteristics	Non atopic (n = 54)	Atopic (n = 23)	P
<b>Age, mean (SD)</b>	69.3 (7.1)	69.7 (7.1)	0.86
<b>Gender, % male</b>	63	57	0.60
<b>Race, (%)</b>			
Caucasian	89	83	
Black/African American	9	13	0.71
Other	2	4	
<b>Education, (%)</b>			
< High School	19	22	
High School	24	9	
Some College	30	39	0.63
Bachelor's Degree	13	13	
At least some Graduate School	15	17	
<b>Smoking History, mean (SD)</b>			
Pack Years	56.8 (28.4)	60.7 (31.0)	0.60
Last Cigarette (Years Since)	13.0 (9.7)	13.4 (8.0)	0.85
<b>Baseline Health Status</b>			
Post Bronchodilator FEV <sub>1</sub> % predicted, mean (SD)	52.4 (16.11)	51.9 (17.29)	0.89
Pre FEV <sub>1</sub> /FVC	0.50 (0.10)	0.52 (0.10)	0.45
Post FEV <sub>1</sub> /FVC	0.51 (0.10)	0.54 (0.11)	0.28
Bronchodilator reversibility, (%)	31.5	30.4	0.93
Chronic Bronchitis (%)	39	35	0.73
Emphysema (%)	57	70	0.32
SGRQ, mean (SD)	38.6 (17.6)	42.0 (20.7)	0.47
MMRC, mean (SD)	2.6 (1.0)	2.5 (1.2)	0.63
<b>Medication list, (%)</b>			
Long acting beta agonist (LABA)	8	4	0.61
Inhaled Corticosteroids (ICS)	19	5	0.12
ICS/LABA combination	44	65	0.10
Long acting muscarinic antagonist	37	43	0.60
Nasal steroids	6	9	0.61
Leukotriene modifiers	8	9	0.88
Theophylline	2	9	0.16
Antihistamine	2	9	0.16
<b>Comorbidities, (%)</b>			
Congestive heart failure	6	9	0.61
Diabetes	19	26	0.45
Cancer	19	22	0.74
Myocardial infarction	11	22	0.22
Hypertension	59	61	0.90
Kidney disease	2	0	0.51

Please note some of the data from the above table were previously published in a manuscript from the CODE cohort [5].

BCSS = Breathlessness, Cough, and Sputum Scale.

SGRQ = St. George's Respiratory Questionnaire.

MMRC = Modified Medical Research Council.

FEV<sub>1</sub> = Forced expiratory volume in 1 second.

FVC = Forced vital capacity.

SD = Standard deviation.

**Table 2 Bivariate association of indoor pollutant concentrations\* and respiratory health**

Bivariate analysis	Non-atopic participants (n = 54)			Atopic participants (n = 23)		
	$\beta$	p	95% CI	$\beta$	p	95% CI
MMRC (dyspnea)	0.11	0.31	[-0.11,0.33]	<b>0.21</b>	<b>0.01</b>	<b>[0.06,0.37]</b>
Rescue medication use	0.06	0.49	[-0.11,0.24]	<b>0.18</b>	<b>0.03</b>	<b>[0.02,0.34]</b>
BCSS	-0.28	0.13	[-0.65,0.09]	0.32	0.09	[-0.05,0.69]
SGRQ	1.04	0.47	[-1.77,3.85]	<b>2.15</b>	<b>0.05</b>	<b>[0.03,4.27]</b>
	OR	p	95% CI	OR	p	95% CI
Wheeze	1.38	0.14	[0.90,2.11]	<b>2.25</b>	<b>0.01</b>	<b>[1.22,4.14]</b>
Nocturnal symptoms	1.00	0.98	[0.55,1.80]	<b>1.76</b>	<b>0.04</b>	<b>[1.02,3.01]</b>
Cough	0.76	0.27	[0.46,1.24]	1.11	0.50	[0.82,1.51]
Phlegm	1.09	0.67	[0.72,1.66]	1.15	0.37	[0.84,1.57]
Severe exacerbations	0.89	0.81	(0.35, 2.28)	1.27	0.21	(0.87, 1.83)

BCSS = Breathlessness, Cough, and Sputum Scale.

SGRQ = St. George's Respiratory Questionnaire.

MMRC = Modified Medical Research Council.

\*ORs and coefficients represent difference in stated outcomes for every 10 point change in PM<sub>2.5</sub>.

Bold values represent statistically significant associations (p <0.05).

and frequency of rescue medication use and ( $\beta = 0.14$ ,  $p = 0.02$ ), with atopy significantly modifying the effect of PM exposure (all p interaction values < 0.1). In addition, a 10  $\mu\text{g}/\text{m}^3$  increase in PM<sub>2.5</sub> concentrations was also associated with increased dyspnea (higher MMRC score,  $\beta = 0.23$ ,  $p < 0.001$ ), worse quality of life (higher SGRQ score,  $\beta = 2.55$ ,  $p = 0.01$ ) and higher likelihood of having frequent wheeze (OR = 2.49,  $p = 0.02$ ) among atopic individuals. PM<sub>2.5</sub> was not significantly associated with health outcomes in non-atopic individuals (Table 3). Adjusting for the use of ICS did not substantially change the results (data not shown).

Though, bedroom PM<sub>2.5</sub> concentrations were not associated with COPD outcomes in main effect analyses

previously published [4], we found statistically significant interactions between bedroom PM<sub>2.5</sub> and atopy for both nocturnal respiratory symptoms and risk for severe exacerbations. Specifically, the relationship between bedroom PM<sub>2.5</sub> concentrations and nocturnal respiratory symptoms differed by atopic status (OR 1.05,  $p = 0.32$  for atopic vs. OR 0.94,  $p = 0.21$  non-atopic) as did the risk for severe exacerbations (OR 1.2,  $p = 0.04$  for atopic vs. OR 0.81,  $p = 0.15$  for non-atopic, interaction p-value for both comparisons <0.1). There were no statistically significant interactions between bedroom PM<sub>2.5</sub> and atopy for other outcomes.

A 20 point increase in NO<sub>2</sub> concentrations in the main living was more likely to be associated with increased

**Table 3 Multivariate analyses of association of indoor pollutant concentrations and respiratory health\***

Multivariate analysis	Non-atopic participants (n = 54)			Atopic participants (n = 23)			int(p)
	$\beta$	p	95% CI	$\beta$	p	95% CI	
MMRC	0.08	0.52	[-0.16, 0.32]	<b>0.23</b>	<b>&lt;0.001</b>	<b>[0.09, 0.34]</b>	0.62
Rescue medication use	0.01	0.90	[-0.18, 0.20]	<b>0.14</b>	<b>0.02</b>	<b>[0.02, 0.26]</b>	<0.001
BCSS	-0.30	0.13	[-0.70, 0.09]	<b>0.44</b>	<b>0.01</b>	<b>[0.11, 0.76]</b>	0.08
SGRQ	1.06	0.45	[-1.67, 3.80]	<b>2.55</b>	<b>0.01</b>	<b>[0.69, 4.41]</b>	0.44
	OR	p	95% CI	OR	p	95% CI	
Frequent wheeze	1.16	0.56	[0.71, 1.88]	<b>2.49</b>	<b>0.02</b>	<b>[1.17, 5.30]</b>	0.17
Nocturnal symptoms	0.60	0.19	[0.29, 1.27]	<b>1.95</b>	<b>0.02</b>	<b>[1.09, 3.48]</b>	0.03
Cough	0.70	0.20	[0.41, 1.20]	1.26	0.23	[0.86, 1.85]	0.28
Phlegm	1.25	0.37	[0.77, 2.05]	1.32	0.15	[0.91, 1.93]	0.79
Severe exacerbations	0.87	0.79	[0.31, 2.42]	<b>2.12</b>	<b>0.03</b>	<b>[1.06, 4.27]</b>	0.63


BCSS = Breathlessness, Cough, and Sputum Scale.

SGRQ = St. George's Respiratory Questionnaire.

MMRC = Modified Medical Research Council.

\*ORs and coefficients represent difference in stated outcomes for every 10 point change in PM<sub>2.5</sub>.

Bold values represent statistically significant associations (p <0.05).



risk of cough in atopic individuals (OR 3.21,  $p = 0.08$ ) compared to non-atopic individuals (OR 0.67,  $p = 0.35$ ),  $p$ -interaction 0.09. There were no significant interactions between bedroom or main living area  $\text{NO}_2$  concentrations and atopy for the remaining health outcomes (data not shown).

## Discussion

To our knowledge, this is the first study investigating whether the presence of atopy modifies the effect of PM exposure on respiratory health in individuals with COPD. It has been previously shown that atopy is prevalent in populations of COPD and is linked to worse respiratory symptoms [20,21]; and that higher PM exposure is associated with worse respiratory outcomes in former smokers with COPD [4]. Our results show that atopic individuals with COPD may be more susceptible to the effects of PM exposure than non-atopic individuals. In particular, higher indoor PM concentration was linked to increased daytime and nocturnal respiratory symptoms and more frequent rescue medication use among atopic individuals but not among non-atopic individuals. This data suggest that atopic patients living with COPD may exhibit a differential response to particulate matter compared to their non-atopic counterparts.

Studies evaluating whether allergic sensitization to aeroallergens is associated with increased susceptibility to the adverse health effects of pollutant exposure in patients with other chronic lung diseases, such as asthma have been conducted however results have been inconsistent. Some epidemiologic studies, similar to our current study in COPD, have found that atopic individuals with asthma may be more susceptible to the effects of PM. For example, in a small study with 19 asthmatic children, Delfino et al. showed that  $\text{PM}_{2.5}$  exposure was associated with a larger reduction in lung function in

children allergic to indoor allergens as compared to those that were non-allergic [22]. It has also been suggested that tobacco smoke exposure is linked to worse respiratory symptoms in atopic children compared to non-atopic children with asthma [23]. In regards to  $\text{NO}_2$ , epidemiological and experimental studies also suggest that atopic status may modify susceptibility to  $\text{NO}_2$  exposure in individuals with asthma, but the results have also been inconsistent [24]. Some studies suggest that there is no differential effect of air pollution exposure on atopic or non-atopic individuals [9] and others have shown that non-atopic individuals may be more susceptible [7,25-27].

There are several potential mechanisms by which the presence of atopy may increase susceptibility to PM exposure. For example, several studies have shown that PM acts as a carrier to some aeroallergens (e.g., cat, dog, birch pollen, and house dust mite allergen) [28,29]. Therefore, the link between higher PM concentrations and health effects may not be due to the direct effects of particulate matter but to the associated increased allergen exposure in sensitized individuals. Furthermore, PM may work as an adjuvant with allergens to incite inflammatory pathways [30]. There are several human and animal experimental studies which support a possible synergistic effect between air pollution and allergen exposure. Individuals with asthma have been shown to experience a greater drop in lung function upon exposure to allergen and air pollutants compared to those exposed to allergen without air pollutants [6,31]. Alberg et al. showed that a combined dosage of PM and Ova allergen injected into mice lead to higher serum anti-Ova IgE concentrations compared with an injection of the allergen Ova alone [32].

In addition to PM being a surrogate for allergen exposure or being linked to a heightened response to allergen exposure, those with atopy may have an inherent predisposition to a heightened response to PM itself. Atopy has been linked to increased underlying eosinophilic airway and systemic inflammation as well as increased bronchial hyper-responsiveness (BHR) even in individuals without asthma [33-35]. This underlying eosinophilic inflammation or increased BHR may predispose individuals to the adverse health effects of pollutant exposure. For example, ozone exposure worsened BHR in a dose dependent fashion in atopic guinea pigs, but did not induce airway hyper-responsiveness in the non-atopic guinea pigs [36]. Being an observational study, we were unable to identify mechanistic underpinnings for our associations which merits further examination.

The moderate size of the study population limits our ability to detect statistically significant interactions and raises the possibility of type II error, which underscores the need to test our hypotheses in future studies. Despite this, we found statistically significant interactions for several outcomes and a consistent trend of stronger adverse



effect of PM concentrations across all outcomes among atopic individuals lending validity to our results that atopic individuals with COPD are more susceptible the effects of PM than non-atopic individuals. Allergen concentrations on PM filters were not available and therefore we were unable to determine whether higher allergen concentrations in PM were linked to worse health outcomes. Furthermore, our assessment of atopic status was limited to perennial allergens and we were not able to investigate whether increasing number of allergic sensitizations or specific sensitizations portends greater risk to the adverse health effects of PM on patients with COPD.

## Conclusion

Our study demonstrates that increasing particulate matter concentrations are more strongly associated with worsening respiratory symptoms for atopic COPD patients than for non-atopic COPD patients. As this may be the first study to look at the importance of allergic sensitization as a modifier of particulate matter as it pertains to COPD, very little clinical guidance currently exists for the differential management of atopics versus non-atopics with COPD. Additional research is needed to support the findings of this study in a larger sample size in order to further characterize the role of an allergic phenotype in COPD and to determine strategies to reduce PM and improve outcomes in this important population.

## Abbreviations

COPD: Chronic obstructive pulmonary disease; PM: Particulate matter; BCSS: Breathlessness, cough, and sputum scale; SGRQ: St. George's respiratory questionnaire; MRC: Medical research council; FEV<sub>1</sub>: Forced expiratory volume in 1 second; FVC: Forced vital capacity; IQR: Interquartile range; SD: Standard deviation; OR: Odds ratio; NO<sub>2</sub>: Nitrogen dioxide.

## Competing interests

The authors declare that they have no competing interests or disclosures.

## Authors' contributions

NNH, MCM, LP, GBD, ECM, NP and PNB provided substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data. DAK, AJB, and RDP contributed to data analysis and interpretation of data. DLW contributed to data acquisition. All authors contributed to revising the manuscript critically for important intellectual content and provided final approval of the version to be published.

## Authors' information

Deepak A Kaji and Andrew J Belli represents two first authors.

## Acknowledgements

This work was supported by grants by NIEHS (ES01578, ES003819, ES015903, ES018176 and ES016819); EPA RD83451001.

## Author details

<sup>1</sup>Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA. <sup>2</sup>Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. <sup>3</sup>Department of Pediatrics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA. <sup>4</sup>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA.

Received: 22 April 2014 Accepted: 26 August 2014  
Published: 10 September 2014

## References

1. Rennard SI: COPD: overview of definitions, epidemiology, and factors influencing its development. *Chest* 1998, **113**(4 Suppl):2355–2415.
2. Hoyert D, Xu J: Deaths: preliminary data for 2011. *Natl Vital Stat Rep* 2012, **61**(6):1–51.
3. Ito K, Barnes PJ: COPD as a disease of accelerated lung aging. *Chest* 2009, **135**(1):173–180.
4. Hansel NN, McCormack MC, Belli AJ, Matsui EC, Peng RD, Aloe C, Paulin L, Williams DL, Diette GB, Breyse PN: In-home air pollution is linked to respiratory morbidity in former smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013, **187**(10):1085–1090.
5. Jamieson DB, Matsui EC, Belli A, McCormack MC, Peng E, Pierre-Louis S, Curtin-Brosnan J, Breyse PN, Diette GB, Hansel NN: Effects of allergic phenotype on respiratory symptoms and exacerbations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2013, **188**(2):187–192.
6. Tunnicliffe WS, Burge PS, Ayres JG: Effect of domestic concentrations of nitrogen dioxide on airway responses to inhaled allergen in asthmatic patients. *Lancet* 1994, **344**(8939–8940):1733–1736.
7. Strachan DP, Butland BK, Anderson HR: Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. *BMJ* 1996, **312**(7040):1195–1199.
8. Baumann LM, Robinson CL, Combe JM, Gomez A, Romero K, Gilman RH, Cabrera L, Hansel NN, Wise RA, Breyse PN, Barnes K, Hernandez JE, Checkley W: Effects of distance from a heavily transited avenue on asthma and atopy in a periurban shantytown in Lima, Peru. *J Allergy Clin Immunol* 2011, **127**(4):875–882.
9. McCormack MC, Breyse PN, Matsui EC, Hansel NN, Peng RD, Curtin-Brosnan J, Williams DL, Wills-Karp M, Diette GB, Center for Childhood Asthma in the Urban Environment: Indoor particulate matter increases asthma morbidity in children with non-atopic and atopic asthma. *Ann Allergy Asthma Immunol* 2011, **106**(4):308–315.
10. Kattan M, Gergen PJ, Eggleston P, Visness CM, Mitchell HE: Health effects of indoor nitrogen dioxide and passive smoking on urban asthmatic children. *J Allergy Clin Immunol* 2007, **120**(3):618–624.
11. Hirsch T, Weiland SK, von Mutius E, Safeca AF, Gräfe H, Csaplovics E, Duhme H, Keil U, Leupold W: Inner city air pollution and respiratory health and atopy in children. *Eur Respir J* 1999, **14**(3):669–677.
12. Middleton ET, Morice AH: Breath carbon monoxide as an indication of smoking habit. *Chest* 2000, **117**(3):758–763.
13. Barr JT, Schumacher GE, Freeman S, LeMoine M, Bakst AW, Jones PW: American translation, modification, and validation of the St. George's Respiratory Questionnaire. *Clin Ther* 2000, **22**(9):1121–1145.
14. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999, **54**(7):581–586.
15. Ferris BG: Epidemiology standardization project (American Thoracic Society). *Am Rev Respir Dis* 1978, **118**(6 Pt 2):1–120.
16. McCarroll ML, Pohle-Krauza RJ, Volsko TA, Martin JL, Krauza ML: Use of the Breathlessness, Cough, and Sputum Scale (BCSS((c))) in pulmonary rehabilitation. *Open Respir Med J* 2013, **7**:1–5.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force: Standardisation of spirometry. *Eur Respir J* 2005, **26**(2):319–338.
18. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999, **159**(1):179–187.
19. Selvin S: In *Statistical Analysis of Epidemiologic Data*. 3rd edition. Edited by Oxford University Press. New York, NY 10016: Oxford University Press; 1996:213–214.
20. Neves MC, Neves YC, Mendes CM, Bastos MN, Camelier AA, Queiroz CF, Mendoza BF, Lemos AC, D'Oliveira Junior A: Evaluation of atopy in patients with COPD. *J Bras Pneumol* 2013, **39**(3):296–305.
21. Fattahi F, ten Hacken NH, Lofdahl CG, Hylkema MN, Timens W, Postma DS, Vonk JM: Atopy is a risk factor for respiratory symptoms in COPD

- patients: results from the EUROSCOP study. *Respir Res* 2013, **14**:10-9921-14-10.
22. Delfino RJ, Quintana PJ, Floro J, Gastanaga VM, Samimi BS, Kleinman MT, Liu LJ, Bufalino C, Wu CF, McLaren CE: **Association of FEV1 in asthmatic children with personal and microenvironmental exposure to airborne particulate matter.** *Environ Health Perspect* 2004, **112**(8):932-941.
  23. Murray AB, Morrison BJ: **It is children with atopic dermatitis who develop asthma more frequently if the mother smokes.** *J Allergy Clin Immunol* 1990, **86**(5):732-739.
  24. Hansel NN, Breyse PN, McCormack MC, Matsui EC, Curtin-Brosnan J, Williams DL, Moore JL, Cuhran JL, Diette GB: **A longitudinal study of indoor nitrogen dioxide levels and respiratory symptoms in inner-city children with asthma.** *Environ Health Perspect* 2008, **116**(10):1428-1432.
  25. Kershaw CR: **Passive smoking, potential atopy and asthma in the first five years.** *J R Soc Med* 1987, **80**(11):683-688.
  26. Palmieri M, Longobardi G, Napolitano G, Simonetti DM: **Parental smoking and asthma in childhood.** *Eur J Pediatr* 1990, **149**(10):738-740.
  27. Chen Y, Rennie DC, Dosman JA: **Influence of environmental tobacco smoke on asthma in nonallergic and allergic children.** *Epidemiology* 1996, **7**(5):536-539.
  28. Ormstad H, Johansen BV, Gaarder PI: **Airborne house dust particles and diesel exhaust particles as allergen carriers.** *Clin Exp Allergy* 1998, **28**(6):702-708.
  29. Ormstad H: **Suspended particulate matter in indoor air: adjuvants and allergen carriers.** *Toxicology* 2000, **152**(1-3):53-68.
  30. D'Amato G, Liccardi G, D'Amato M, Cazzola M: **Respiratory allergic diseases induced by outdoor air pollution in urban areas.** *Monaldi Arch Chest Dis* 2002, **57**(3-4):161-163.
  31. Vagaggini B, Taccola M, Cianchetti S, Carnevali S, Bartoli ML, Bacci E, Dente FL, Di Franco A, Giannini D, Paggiaro PL: **Ozone exposure increases eosinophilic airway response induced by previous allergen challenge.** *Am J Respir Crit Care Med* 2002, **166**(8):1073-1077.
  32. Alberg T, Cassee FR, Groeng E, Dybing E, Løvik M: **Fine ambient particles from various sites in Europe exerted a greater IgE adjuvant effect than coarse ambient particles in a mouse model.** *J Toxicol Environ Health A* 2008, **72**(1):1-13.
  33. Suh DI, Koh YY: **Relationship between atopy and bronchial hyperresponsiveness.** *Allergy Asthma Immunol Res* 2013, **5**(4):181-188.
  34. Backer V, Ulrik CS, Hansen KK, Laursen EM, Dirksen A, Bach-Mortensen N: **Atopy and bronchial responsiveness in random population sample of 527 children and adolescents.** *Ann Allergy* 1992, **69**(2):116-122.
  35. Mensinga TT, Schouten JP, Weiss ST, Van der Lende R: **Relationship of skin test reactivity and eosinophilia to level of pulmonary function in a community-based population study.** *Am Rev Respir Dis* 1992, **146**(3):638-643.
  36. Schlesinger RB, Cohen MD, Gordon T, Nadziejko C, Zelikoff JT, Sisco M, Regal JF, Menache MG: **Ozone differentially modulates airway responsiveness in atopic versus nonatopic guinea pigs.** *Inhal Toxicol* 2002, **14**(5):431-457.

doi:10.1186/1471-2466-14-147

**Cite this article as:** Kaji et al.: Indoor pollutant exposure is associated with heightened respiratory symptoms in atopic compared to non-atopic individuals with COPD. *BMC Pulmonary Medicine* 2014 **14**:147.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

